Literature DB >> 2998590

Non-cytotoxic activity of pyran copolymer-induced macrophages associated with potentiation of tumour vaccine in recipient mice.

T Kataoka, F Oh-hashi.   

Abstract

Mice inoculated with both L1210 murine tumour vaccine and pyran copolymer were more resistant to L1210 than those inoculated with either of these agents alone. Rabbit anti-mouse thymocyte globulin and silica reduced the augmented resistance of these mice, suggesting the involvement of activated anti-tumour T cells and macrophages in the augmented resistance. We studied the activation of these two cells separately and examined the possible contribution of pyran copolymer-induced peritoneal cells to the augmented resistance to an inoculation of live tumour. Pyran copolymer-induced peritoneal cells endowed the tumour vaccine-primed mice, but not unprimed mice, with resistance to implanted L1210 and, among those peritoneal cell populations, macrophages but not T cells were responsible for this effect since the activity was associated with a cell population which was adherent to nylon wool columns, sensitive to silica and insensitive to anti-Thy 1.2 antibody plus complement. The pyran copolymer-induced peritoneal cells had very little antiproliferative activity when tested against L1210 in vitro and mice inoculated with these peritoneal cells did not survive a challenge of live L1210 cells much longer (less than 1 day) than L1210 inoculated control mice. Furthermore, the survival of L1210 vaccine-primed mice inoculated with one-tenth the amount of live L1210 (10(2)) was still much shorter than that of mice primed with L1210 vaccine plus pyran copolymer and challenged with ten times as many (10(3)) live L1210 cells. Therefore, direct tumoricidal activity was probably not a major factor in the in vivo immunological augmenting activity of the pyran copolymer-induced macrophages.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2998590     DOI: 10.1007/bf00199776

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  13 in total

1.  Specific and nonspecific stimulation of resistance to the growth and metastasis of the line 1 lung carcinoma.

Authors:  J M Yuhas; R E Toya; E Wagner
Journal:  Cancer Res       Date:  1975-01       Impact factor: 12.701

2.  Immunotherapy of established micrometastases with Bacillus Calmette-Guérin tumor cell vaccine.

Authors:  M G Hanna; L C Peters
Journal:  Cancer Res       Date:  1978-01       Impact factor: 12.701

3.  Experimental evaluation of potential anticancer agents. XIX. Sensitivity of nondividing leukemic cell populations to certain classes of drugs in vivo.

Authors:  F M Schabel; H E Skipper; M W Trader; W S Wilcox
Journal:  Cancer Chemother Rep       Date:  1965-10

4.  Augmentation of specific macrophage-mediated cytotoxicity: correlations with agents which enhance antitumor resistance.

Authors:  R M Schultz; J D Papamatheakis; W A Stylos; M A Chirigos
Journal:  Cell Immunol       Date:  1976-08       Impact factor: 4.868

5.  Potentiation of concanavalin A-bound L1210 vaccine in vivo by chemotherapeutic agents.

Authors:  T Kataoka; H Kobayashi; Y Sakurai
Journal:  Cancer Res       Date:  1978-05       Impact factor: 12.701

6.  Eradication by immunization with mycobacterial vaccines and tumor cells of microscopic metastases remaining after surgery.

Authors:  B Zbar; G Canti; M P Ashley; H J Rapp; J T Hunter; E Ribi
Journal:  Cancer Res       Date:  1979-05       Impact factor: 12.701

7.  Immunotherapeutic response of concanavalin A-bound L1210 vaccine enhanced by a streptococcal immunopotentiator, OK-432.

Authors:  T Kataoka; F Oh-hashi; Y Sakurai
Journal:  Cancer Res       Date:  1979-07       Impact factor: 12.701

8.  Immunoprophylactic and immunotherapeutic response by concanavalin A-bound tumor vaccine enhanced by chemotherapeutic agents eliminating possible suppressors.

Authors:  T Kataoka; K Ogihara; Y Sakurai
Journal:  Cancer Res       Date:  1980-10       Impact factor: 12.701

9.  Immunogenicity and amplifier cell production by tumor vaccines enhanced by concanavalin A.

Authors:  T Kataoka; F Oh-Hashi; Y Sakurai
Journal:  Gan       Date:  1982-04

10.  Relative contribution of antiproliferative and host immunity-associated activity of mouse interferon in murine tumor therapy.

Authors:  T Kataoka; F Oh-hashi; Y Sakurai; K Usuki; N Ida
Journal:  Cancer Res       Date:  1984-12       Impact factor: 12.701

View more
  1 in total

1.  I-Ad antigen expression of pyran copolymer-induced peritoneal cells in tumor vaccine-primed mice and its association with the host antitumor response.

Authors:  F Oh-hashi; T Kataoka; T Taniyama
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.